Lewiecki E, et al “Continued fracture risk reduction after 12 months of romosozumab followed by denosumab through 36 months in the phase 3 FRAME (FRActure study in postmenopausal woMen with ostEoporosis) extension” ASBMR 2017; Abstract 1071.Saag K, et al “A randomized alendronate-controlled trial of romosozumab: results of the phase 3 ARCH study (Active-contRolled fraCture study in postmenopausal women with osteoporosis at High risk)” ASBMR 2017; Abstract LB-1162.

Source Reference: Saag KG, et al “Romosozumab or alendronate for fracture prevention in women with osteoporosis” N Engl J Med 2017;DOI:10.1056/NEJMoa1708322.